Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Hangzhou Tigermed Consulting - H (3347.HK)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (HK$)	Price Target (HK$)	Rating
2021-08-13	141.10	246.76	Buy
2021-12-15	110.00	173.82	Buy
2022-04-11	89.40	138.82	Buy
2022-08-26	77.05	126.22	Buy
2022-09-20	66.85	117.00	Buy
2022-10-26	56.70	107.00	Buy
2023-03-29	78.70	114.00	Buy
2023-09-28	44.05	50.00	Neutral
2023-10-30	45.55	45.70	Neutral
2024-03-15	31.55	36.30	Neutral
2024-04-25	31.00	33.40	Neutral
2024-06-12	32.30	46.20	Buy
2024-08-28	29.85	42.50	Buy
2024-11-05	38.80	47.00	Buy

Disclosures

Market capitalisation is calculated by multiplying the current share price by the sum of A and H shares.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.